Alzamend Neuro News - ALZN

Company Name	Stock Ticker Symbol	Market	Type
Alzamend Neuro Inc	ALZN	NASDAQ	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	0.0344	5.02%	0.7194	12:35:53

Open Price	Low Price	High Price	Close Price	Prev Close
0.7075	0.685	0.7295		0.685

more quote information »

Recent News

Date	Time	Source	Heading
3/07/2024	16:30	EDGAR2	Form 8-K - Current report
2/02/2024	16:30	EDGAR2	Form 8-K - Current report
1/05/2024	16:30	EDGAR2	Form 8-K - Current report
12/15/2023	16:30	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/11/2023	08:00	BW	Alzamend Neuro Receives FDA “Study May Proceed” Notification..
11/20/2023	08:00	BW	Alzamend Neuro Receives FDA “Study May Proceed” Notification..
11/16/2023	16:30	EDGAR2	Form 8-K - Current report
11/16/2023	08:00	BW	Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid..
11/13/2023	08:00	BW	Alzamend Neuro Submits IND Application for a Phase IIA..
10/30/2023	16:30	EDGAR2	Form 8-K - Current report
10/30/2023	08:00	BW	Alzamend Neuro Announces Reverse Stock Split
10/23/2023	08:00	BW	Alzamend Neuro Submits IND Application for a Phase IIA..
10/02/2023	08:00	BW	Alzamend Neuro Receives FDA “Study May Proceed” Notification..
9/29/2023	16:30	EDGAR2	Form 8-K - Current report
9/26/2023	18:01	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
9/22/2023	16:30	EDGAR2	Form 8-K - Current report
9/22/2023	08:00	BW	Alzamend Neuro Granted Extension by Nasdaq Panel to Regain..
9/13/2023	17:09	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
9/08/2023	17:05	EDGAR2	Form 424B5 - Prospectus [Rule 424(b)(5)]
9/08/2023	17:00	EDGAR2	Form 8-K - Current report
9/01/2023	16:30	EDGAR2	Form DEFA14A - Additional definitive proxy soliciting..
8/30/2023	08:00	BW	Alzamend Neuro Submits IND Application for Phase IIA..
8/24/2023	16:30	EDGAR2	Form DEF 14A - Other definitive proxy statements
8/16/2023	16:30	EDGAR2	Form 8-K - Current report
8/11/2023	00:15	EDGAR2	Form EFFECT - Notice of Effectiveness
8/10/2023	16:30	EDGAR2	Form PRE 14A - Other preliminary proxy statements
8/07/2023	16:30	EDGAR2	Form 8-K - Current report
8/02/2023	16:31	EDGAR2	Form S-3 - Registration statement under Securities Act of..
7/27/2023	16:56	EDGAR2	Form 10-K - Annual report [Section 13 and 15(d), not S-K..
6/22/2023	08:00	BW	Alzamend Neuro Announces Positive Phase IIA Clinical Trial..
6/13/2023	08:00	BW	Alzamend Neuro CEO Stephan Jackman to Participate on the..